Literature DB >> 27661418

Zinc transporters protein level in postmortem brain of depressed subjects and suicide victims.

Anna Rafalo-Ulinska1, Joanna Piotrowska2, Agata Kryczyk2, Włodzimierz Opoka2, Magdalena Sowa-Kucma3, Paulina Misztak4, Grazyna Rajkowska5, Craig A Stockmeier6, Wojciech Datka7, Gabriel Nowak4, Bernadeta Szewczyk8.   

Abstract

BACKGROUND: Major depressive disorder (MDD) is a serious psychiatric illness, associated with an increasing rate of suicide. The pathogenesis of depression may be associated with the disruption of zinc (Zn) homeostasis. In the brain, several proteins that regulate Zn homeostasis are present, including Zn transporters (ZnTs) which remove Zn from the cytosol. The present study was designed to investigate whether depression and suicide are associated with alterations in the expression of the ZnTs protein.
METHODS: Protein levels of ZnT1, ZnT3, ZnT4, ZnT5 and ZnT6 were measured in postmortem brain tissue from two different cohorts. Cohort A contained 10 subjects diagnosed with MDD (7 were suicide victims) and 10 psychiatrically-normal control subjects and cohort B contained 11 non-diagnosed suicide victims and 8 sudden-death control subjects. Moreover, in cohort A we measured protein level of NMDA (GluN2A subunit), AMPA (GluA1 subunit) and 5-HT1A receptors and PSD-95. Proteins were measured in the prefrontal cortex (PFC) using Western blotting. In addition, Zn concentration was measured using a voltammetric method.
RESULTS: There was a significant increase in protein levels of ZnT1, ZnT4, ZnT5 in the PFC in MDD, relative to control subjects, while ZnT3 protein level was decreased in MDD. There was no significant difference in the Zn concentration in the PFC between control and MDD subjects. Similarly, in the PFC of suicide victims (non-diagnosed), an increase in protein levels of ZnT1, ZnT4, ZnT5 and ZnT6 was observed. Conversely, protein levels of ZnT3 were decreased in both suicide victims and subjects with MDD, in comparison with control subjects. There was also a significant decrease in the protein level of GluA1, GluN2A, PSD-95 and 5-HT1A in MDD.
CONCLUSIONS: Our studies suggest that alterations in Zn transport proteins are associated with the pathophysiology of MDD and suicide.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  5-HT1A; Glutamate receptors; Major depressive disorder; Suicide; Zinc; Zn transporters

Mesh:

Substances:

Year:  2016        PMID: 27661418      PMCID: PMC5107146          DOI: 10.1016/j.jpsychires.2016.09.008

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  72 in total

Review 1.  Neurotrophins: roles in neuronal development and function.

Authors:  E J Huang; L F Reichardt
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

Review 2.  Characterization of biometal profiles in neurological disorders.

Authors:  Stefanie Pfaender; Andreas M Grabrucker
Journal:  Metallomics       Date:  2014-05       Impact factor: 4.526

3.  The involvement of the GPR39-Zn(2+)-sensing receptor in the pathophysiology of depression. Studies in rodent models and suicide victims.

Authors:  Katarzyna Młyniec; Urszula Doboszewska; Bernadeta Szewczyk; Magdalena Sowa-Kućma; Paulina Misztak; Wojciech Piekoszewski; Franciszek Trela; Beata Ostachowicz; Gabriel Nowak
Journal:  Neuropharmacology       Date:  2013-12-10       Impact factor: 5.250

4.  Nutrient intakes and the common mental disorders in women.

Authors:  Felice N Jacka; Michael Maes; Julie A Pasco; Lana J Williams; Michael Berk
Journal:  J Affect Disord       Date:  2012-03-06       Impact factor: 4.839

Review 5.  Current understanding of ZIP and ZnT zinc transporters in human health and diseases.

Authors:  Taiho Kambe; Ayako Hashimoto; Shigeyuki Fujimoto
Journal:  Cell Mol Life Sci       Date:  2014-04-08       Impact factor: 9.261

6.  Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder.

Authors:  J A Cobb; K O'Neill; J Milner; G J Mahajan; T J Lawrence; W L May; J Miguel-Hidalgo; G Rajkowska; C A Stockmeier
Journal:  Neuroscience       Date:  2015-12-30       Impact factor: 3.590

7.  Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.

Authors:  M Maes; E Bosmans; R De Jongh; G Kenis; E Vandoolaeghe; H Neels
Journal:  Cytokine       Date:  1997-11       Impact factor: 3.861

8.  Zinc in depressive disorder.

Authors:  I J McLoughlin; J S Hodge
Journal:  Acta Psychiatr Scand       Date:  1990-12       Impact factor: 6.392

9.  Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression.

Authors:  Beata Karolewicz; Katalin Szebeni; Tempestt Gilmore; Dorota Maciag; Craig A Stockmeier; Gregory A Ordway
Journal:  Int J Neuropsychopharmacol       Date:  2008-06-23       Impact factor: 5.176

Review 10.  The role of NMDA receptors in the pathophysiology and treatment of mood disorders.

Authors:  Mehdi Ghasemi; Cristy Phillips; Ludwig Trillo; Zurine De Miguel; Devsmita Das; Ahmad Salehi
Journal:  Neurosci Biobehav Rev       Date:  2014-09-16       Impact factor: 8.989

View more
  11 in total

1.  Alterations in brain synaptic proteins and mRNAs in mood disorders: a systematic review and meta-analysis of postmortem brain studies.

Authors:  Edison Leung; Ethan W Lau; Andi Liang; Constanza de Dios; Robert Suchting; Linda Östlundh; Joseph C Masdeu; Masahiro Fujita; Marsal Sanches; Jair C Soares; Sudhakar Selvaraj
Journal:  Mol Psychiatry       Date:  2022-01-13       Impact factor: 13.437

Review 2.  Promising leads and pitfalls: a review of dietary supplements and hormone treatments to prevent postpartum blues and postpartum depression.

Authors:  Yekta Dowlati; Jeffrey H Meyer
Journal:  Arch Womens Ment Health       Date:  2020-11-17       Impact factor: 3.633

Review 3.  The role of labile Zn2+ and Zn2+-transporters in the pathophysiology of mitochondria dysfunction in cardiomyocytes.

Authors:  Belma Turan; Erkan Tuncay
Journal:  Mol Cell Biochem       Date:  2020-11-22       Impact factor: 3.396

Review 4.  Interaction between Zinc, GPR39, BDNF and Neuropeptides in Depression.

Authors:  Katarzyna Mlyniec
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

5.  Allosteric Inhibition of Serotonin 5-HT7 Receptors by Zinc Ions.

Authors:  Grzegorz Satała; Beata Duszyńska; Tomasz Lenda; Gabriel Nowak; Andrzej J Bojarski
Journal:  Mol Neurobiol       Date:  2017-04-28       Impact factor: 5.590

Review 6.  Why and how to investigate the role of protein phosphorylation in ZIP and ZnT zinc transporter activity and regulation.

Authors:  T E Thingholm; L Rönnstrand; P A Rosenberg
Journal:  Cell Mol Life Sci       Date:  2020-02-19       Impact factor: 9.261

7.  Imipramine Influences Body Distribution of Supplemental Zinc Which May Enhance Antidepressant Action.

Authors:  Anna Rafało-Ulińska; Ewa Poleszak; Aleksandra Szopa; Anna Serefko; Magdalena Rogowska; Ireneusz Sowa; Magdalena Wójciak; Bożena Muszyńska; Agata Krakowska; Joanna Gdula-Argasińska; Katarzyna Kała; Barbara Jasiewicz; Włodzimierz Opoka; Bernadeta Szewczyk; Gabriel Nowak
Journal:  Nutrients       Date:  2020-08-20       Impact factor: 5.717

8.  Genetic Inhibition of Plppr5 Aggravates Hypoxic-Ischemie-Induced Cortical Damage and Excitotoxic Phenotype.

Authors:  Yuxiao Sun; Mei-Fang Jin; Lili Li; Yueying Liu; Dandan Wang; Hong Ni
Journal:  Front Neurosci       Date:  2022-03-24       Impact factor: 4.677

9.  Zinc Deficiency Blunts the Effectiveness of Antidepressants in the Olfactory Bulbectomy Model of Depression in Rats.

Authors:  Anna Rafało-Ulińska; Bartłomiej Pochwat; Paulina Misztak; Ryszard Bugno; Agata Kryczyk-Poprawa; Włodzimierz Opoka; Bożena Muszyńska; Ewa Poleszak; Gabriel Nowak; Bernadeta Szewczyk
Journal:  Nutrients       Date:  2022-06-30       Impact factor: 6.706

Review 10.  Insights into Potential Targets for Therapeutic Intervention in Epilepsy.

Authors:  Cecilia Zavala-Tecuapetla; Manola Cuellar-Herrera; Hiram Luna-Munguia
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.